Pharma group Novartis has posted lower figures for the first half of 2012.

Net profit is down 9 percent compared with the same time last year, ringing in at over $5.5 billion.

The Basel-based giant blamed the figures on weak earnings in generic drugs.

It also said the strengthening dollar impacted its bottom line.